6 Health Care Stocks to Buy for the Second Half of 2020, According to Barron’s Investing Experts

The members of the Barron’s Roundtable see numerous bargains among health-care stocks. The conversations below are excerpted from our recent Midyear Roundtable, published on July 10. To read the entire Roundtable, click here.I have three health-care names. GlaxoSmithKline [ticker: GSK] yields almost 5% and offers single-digit organic earnings growth. Gilead Sciences [GILD] has a 3.

We expect Bristol-Myers to generate $41.8 billion of revenue this year, and earn about $6.20 a share, versus $4.69 in 2019. Revenue will get a one-time pop of about 60% because of last year’s acquisition of Celgene. For next year, we have modeled 7.5% revenue growth on the conservative side, or $45 billion, and earnings after taxes of $16.5 billion, or $7.33 a share. Using more-optimistic assumptions, the company could earn $17 billion, or $7.55 a share, on $45.6 billion of revenue.

$PFE

Big fan of $GILD

I think I'll buy some bread instead.

Россия Последние новости, Россия Последние новости

Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей

Primary care company Oak Street Health S-1 IPO filing analysis - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web.
Источник: BusinessInsider - 🏆 729. / 51 Прочитайте больше »

Coronavirus impact on primary care: Iora Health, ChenMed, One Medical - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web. Anyone who thinks these companies aren't putting profits before patients is kidding themselves.
Источник: BusinessInsider - 🏆 729. / 51 Прочитайте больше »